A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance
- PMID: 35398462
- DOI: 10.1016/j.jhep.2022.03.032
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance
Abstract
Background & aims: After hepatitis B surface antigen (HBsAg) seroclearance, the risk of hepatocellular carcinoma (HCC) remains, and the optimal surveillance strategy has yet to be determined. Herein, we aimed to evaluate incidence and risk factors for HCC and establish a novel prediction model for HCC development after HBsAg seroclearance.
Methods: A total of 1,443 patients with chronic hepatitis B who achieved HBsAg seroclearance between 1991 and 2020 were retrospectively screened for study eligibility. The data from 831 of these patients were included in the final analysis. A prediction model was developed based on multivariable Cox models. Harrell's C-index and a time-dependent AUROC were used for discrimination. Bootstrap analysis was performed for internal validation.
Results: Overall, 40 patients (4.8%) developed HCC after HBsAg seroclearance during a follow-up of 4,644 person-years (0.86%/year). Age at HBsAg seroclearance, presence of cirrhosis, family history of HCC, and more-than-moderate alcohol consumption were independently predictive of HCC, and these 4 independent variables were used to develop the prediction model. The C-index of the model was 0.804. The time-dependent AUROCs of the score for HCC prediction at 5, 10, and 15 years were 0.799, 0.835, and 0.817, respectively. The score also showed good discrimination in the internal validation and sensitivity analysis.
Conclusions: The novel prediction model based on age, cirrhosis, family history of HCC, and alcohol consumption enables reliable risk estimation of HCC after HBsAg seroclearance and may serve as a useful reference for decision-making in HCC surveillance for HBsAg-cleared patients.
Lay summary: After spontaneous hepatitis B surface antigen (HBsAg) seroclearance, the risk of hepatocellular carcinoma (HCC) remains. Age at HBsAg seroclearance, presence of cirrhosis, family history of HCC, and more-than-moderate alcohol consumption were independently associated with HCC development after HBsAg seroclearance. The novel prediction model using these 4 variables enables reliable risk estimation of HCC and serves as a useful reference for decision-making in HCC surveillance and management for HBsAg-cleared patients.
Keywords: Chronic hepatitis B; HBsAg seroclearance; Hepatocellular carcinoma; Prediction model.
Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations.J Hepatol. 2022 Dec;77(6):1722-1724. doi: 10.1016/j.jhep.2022.05.032. Epub 2022 Jun 9. J Hepatol. 2022. PMID: 35690263 No abstract available.
-
Reply to: "A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Considerations".J Hepatol. 2022 Dec;77(6):1724-1725. doi: 10.1016/j.jhep.2022.08.026. Epub 2022 Sep 2. J Hepatol. 2022. PMID: 36058364 No abstract available.
-
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?J Hepatol. 2023 Oct;79(4):e154-e155. doi: 10.1016/j.jhep.2023.01.021. Epub 2023 Feb 1. J Hepatol. 2023. PMID: 36736735 No abstract available.
-
Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: Has the correct patient cohort been targeted?'.J Hepatol. 2023 Oct;79(4):e155-e157. doi: 10.1016/j.jhep.2023.06.005. Epub 2023 Jun 27. J Hepatol. 2023. PMID: 37385474 No abstract available.
Similar articles
-
Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.J Hepatol. 2015 May;62(5):1092-9. doi: 10.1016/j.jhep.2014.11.031. Epub 2014 Nov 28. J Hepatol. 2015. PMID: 25445399
-
Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.Clin Transl Gastroenterol. 2021 Jan 11;12(1):e00290. doi: 10.14309/ctg.0000000000000290. Clin Transl Gastroenterol. 2021. PMID: 33433118 Free PMC article.
-
Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.J Hepatol. 2017 Nov;67(5):902-908. doi: 10.1016/j.jhep.2017.06.019. Epub 2017 Jun 24. J Hepatol. 2017. PMID: 28652084
-
Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.Aliment Pharmacol Ther. 2016 Jun;43(12):1253-61. doi: 10.1111/apt.13634. Epub 2016 Apr 27. Aliment Pharmacol Ther. 2016. PMID: 27117732
-
What can we learn from hepatitis B virus clinical cohorts?Liver Int. 2015 Jan;35 Suppl 1:91-9. doi: 10.1111/liv.12716. Liver Int. 2015. PMID: 25529093 Review.
Cited by
-
Targetoid Primary Liver Malignancy in Chronic Liver Disease: Prediction of Postoperative Survival Using Preoperative MRI Findings and Clinical Factors.Korean J Radiol. 2023 Mar;24(3):190-203. doi: 10.3348/kjr.2022.0560. Epub 2023 Jan 19. Korean J Radiol. 2023. PMID: 36788766 Free PMC article.
-
Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine.Pharmaceutics. 2022 Aug 23;14(9):1760. doi: 10.3390/pharmaceutics14091760. Pharmaceutics. 2022. PMID: 36145508 Free PMC article. Review.
-
Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history.J Gastroenterol. 2025 Jan;60(1):107-117. doi: 10.1007/s00535-024-02162-3. Epub 2024 Oct 22. J Gastroenterol. 2025. PMID: 39438326
-
Mapping the knowledge domains of literature on hepatocellular carcinoma and liver failure: a bibliometric approach.Front Oncol. 2025 Apr 16;15:1529297. doi: 10.3389/fonc.2025.1529297. eCollection 2025. Front Oncol. 2025. PMID: 40308492 Free PMC article.
-
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic.Hepatology. 2025 Jan 14:10.1097/HEP.0000000000001227. doi: 10.1097/HEP.0000000000001227. Online ahead of print. Hepatology. 2025. PMID: 39808821 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical